NCT04771130 2026-04-14
A Study of BGB-11417 in Participants With Myeloid Malignancies
BeOne Medicines
Phase 1/2 Recruiting
BeOne Medicines
AstraZeneca
Centre Hospitalier Universitaire Vaudois
AbbVie
Hospices Civils de Lyon
King's College Hospital NHS Trust
Novartis
Memorial Sloan Kettering Cancer Center
F2G Biotech GmbH
Merck Sharp & Dohme LLC